Premium
P4‐078: CONCORDE‐AD: AN INTERNATIONAL NETWORK OF COHORTS FOR BETTER UNDERSTANDING OF ALZHEIMER'S DISEASE
Author(s) -
Burnham Samantha C.,
Coloma Preciosa M.,
Dartigues Jean-François,
Doody Rachelle,
Hansson Oskar,
Helmer Catherine,
Kass Joseph S.,
Masters Colin L.,
Palmqvist Sebastian,
Pavlik Valory N.,
Petersen Ronald C.,
Roberts Rosebud O.,
Schaeuble Barbara,
Sano Mary
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.2481
Subject(s) - context (archaeology) , disease , cohort , dementia , gerontology , cohort study , socioeconomic status , psychology , medicine , population , environmental health , geography , pathology , archaeology
Compared to scoring 1, scoring 5 on the ADFlag scale conveyed a 19.66-fold increase (15.98-24.18; Chisq<0.0001) in the odds for incipient AD diagnostic by A+T+N+ criteria, and scoring 4 a 2.96-fold increase (2.62-3.33; Chisq<0.0001). Patients scoring 5 on the ADFlag scale were all part of the Alzheimer’s pathophysiologic continuum (A+). Together, patients scoring either 4 or 5 represented 73% of all A+ patients, including 63.63% of the A+T+N+ or A+T+N(incipient AD). Moreover, we found that an ADFlag score of 4 at baseline significantly increased the odds for conversion 4.17-fold compared to patients scoring 1 (3.61-4.80; Chisq<0.0001) and 8.34-fold compared to patients scoring 3 (6.37-10.91; Chisq<0.0001). A generalized regression predictive model confirmed the association between conversion to AD and scoring 4 on the ADFlag scale. Conclusions: ADFlag has significant prognostic value and it’s use as a stratification tool to prescreen aMCI patients into preventive or therapeutic trials may enhance their chance of success.